<DOC>
	<DOCNO>NCT02099981</DOCNO>
	<brief_summary>Diabetic retinopathy lead cause blindness develop world . The cause disease poorly understood . One early change occur retina diabetic patient , well overt retinopathy observe , reduction light-evoked increase blood flow retinal vessel . The loss vascular response may lead retinal hypoxia suggest hypoxia could principal cause diabetic retinopathy . The long-term goal project determine whether decreased blood flow diabetic patient result retinal hypoxia contributes development diabetic retinopathy whether restoration normal blood flow diabetic patient slow prevents development retinopathy .</brief_summary>
	<brief_title>Restoration Retinal Vascular Responses Type 1 Diabetic Patients</brief_title>
	<detailed_description>The immediate goal propose project determine whether administration aminoguanidine ( AG ) restore light -- evoked vasodilation retinas patient without advanced retinopathy . We also determine whether AG improve contrast sensitivity diabetic patient . The proposed experiment first step develop new therapy prevent diabetic retinopathy . Study participant ask come University Minnesota three ( 3 ) occasion ( visit last 2 , 5 3 hour respectively ) . Visit 1 . During screen visit ( first shortest visit ) , consent obtain baseline lab collect ( Hemoglobin A1c Creatinine ) . Demographic information ( date birth , gender , race ) , subject characteristic ( weight , height , blood pressure pulse ) relevant medical history record . Visit 2 . Vessel dilation test : Control diabetic subject present Ophthalmology Research Unit University Minnesota . Prior image examination , subject receive dilate eye drop ( 1 % Tropicamide ) prevent accommodation pupil brief eye exam perform . Measurement rest vessel diameter light -- evoked vessel dilation make use Imedos Systems `` Dynamic Vessel Analyzer '' . Subjects instructed look fixation spot 350 sequence fundus image acquire baseline stimulation period . After completion initial vasodilation measurement , control diabetic subject give 150 mg AG orally measurement rest vessel diameter light -- evoked vasodilation repeat 90 minute later . Visit 3 . Contrast sensitivity testing : Contrast sensitivity assess un-dilated control diabetic subject . Contrast sensitivity determine AG administration use CSV-100 test chart ( VectorVision ) measure 3 , 6 , 12 , 18 cycle per degree .</detailed_description>
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Pimagedine</mesh_term>
	<criteria>Type 1 diabetes 18 65 year age Diabetes duration 5 20 year . Normal report minor finding dilate eye exam Healthy subject medication Current diagnosis history : hypertension dyslipidemia epilepsy glaucoma ocular disease renal insufficiency/failure ( creatinine &gt; 1.5 mg/dL ) pregnancy breastfeed . smoker</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Diabetic</keyword>
	<keyword>Retinopathy</keyword>
	<keyword>Ophthalmology</keyword>
	<keyword>Eye</keyword>
	<keyword>Eyes</keyword>
</DOC>